Oruka Therapeutics, Inc. (ORKA)
NASDAQ: ORKA · Real-Time Price · USD
9.56
-0.20 (-2.00%)
May 9, 2025, 11:01 AM - Market open
Company Description
Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications.
Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 1 trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F for the treatment of PsO, psoriatic arthritis, and other conditions.
The company also develops ORKA-003 for targeting an undisclosed pathway; and ORKA-021, a sequential combination regimen of ORKA-002 and ORKA-001.
Oruka Therapeutics, Inc. is headquartered in Menlo Park, California.
Oruka Therapeutics, Inc.
| Country | United States |
| Founded | 2004 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 28 |
| CEO | Lawrence Klein |
Contact Details
Address: 855 Oak Grove Avenue, Suite 100 Menlo Park, California 94025 United States | |
| Phone | (650) 606-7910 |
| Website | orukatx.com |
Stock Details
| Ticker Symbol | ORKA |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000907654 |
| CUSIP Number | 687604108 |
| ISIN Number | US6876041087 |
| Employer ID | 36-3855489 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Lawrence Otto Klein Ph.D. | President, Chief Executive Officer and Director |
| Paul T. Quinlan | General Counsel and Secretary |
| Dr. Joana Goncalves M.D. | Chief Medical Officer |
| Laura Sandler | Senior Vice President of Operations and Boston Site Head |
| Alan Lada | Vice President of Investor Relations |
| Christopher Finch | Vice President of Corporate Development and Strategy |
| Dr. Rajiv Panwar | Vice President and Head of Chemistry, Manufacturing and Controls |
| Dr. Joe Senn Ph.D. | Senior Vice President of Nonclinical Research and Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 18, 2025 | ARS | Filing |
| Apr 18, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 18, 2025 | DEF 14A | Other definitive proxy statements |
| Mar 11, 2025 | EFFECT | Notice of Effectiveness |
| Mar 10, 2025 | SCHEDULE 13D/A | Filing |
| Mar 6, 2025 | POS AM | Post-Effective amendments for registration statement |
| Mar 6, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 6, 2025 | 10-K | Annual Report |
| Feb 27, 2025 | SCHEDULE 13G/A | Filing |
| Feb 5, 2025 | 8-K | Current Report |